NCT00091559View on ClinicalTrials.gov

Oral SAHA (Suberoylanilide Hydroxamic Acid) in Advanced Cutaneous T-cell Lymphoma (0683-001)

PHASE2CompletedINTERVENTIONAL
Enrollment

74

Participants

Timeline

Start Date

February 3, 2005

Primary Completion Date

November 23, 2005

Study Completion Date

March 13, 2006

Conditions
Cutaneous T-cell LymphomaSezary SyndromeMycosis Fungoides
Interventions
DRUG

MK0683, vorinostat, Suberoylanilide Hydroxamic Acid (SAHA) / Duration of Treatment 6 Months

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00091559 - Oral SAHA (Suberoylanilide Hydroxamic Acid) in Advanced Cutaneous T-cell Lymphoma (0683-001) | Biotech Hunter | Biotech Hunter